Assessing and Enhancing HIV Vaccine Trial (HVT) Consent Preparedness Among Street Drug Users

Similar documents
Enhancing HIV Vaccine Trial Consent Preparedness Among Drug Users

Goodness-of-Fit Ethics Theory and Methods for Enhancing the Responsible Conduct of HIV and Drug Abuse Research

Addiction Research Ethics and the Belmont Principles: Do Drug Users Have a Different Moral Voice?

Self-Consent for HIV Prevention Research Involving Sexual and Gender Minority Youth

Quantitative Approaches to ERRE

Understanding Clinical Trials

Substance Abuse Treatment, Integrated Care, & the HIV Care Continuum

The Johns Hopkins Bloomberg School of Public Health

Additional North Carolina Projects

Hepatitis C treatment program improves access to housing, income and healthcare

Notes Testing: Follow Up and Giving Results

Assessing HIV Stigma Among Opioid- Dependent Individuals. Under Community Supervision

AIDS. health concern. As of 2005, a cure for HIV/AIDS remains to be found. While medical

Medical Case Management Training Series Module 1. Anissa Ray & Vadim Kogan

IRB Approval From: 3/8/2010 To: 10/28/2010

Alliance A Mrinal Gounder, MD Study Chair NCT #: NCT

What Are HIV & AIDS? Together, we can change the course of the HIV epidemic one woman at a time.

Does the Addition of HCV Testing to a Rapid HIV Testing Program Impact HIV Test Acceptance? A Randomized Controlled Trial.

PUBLIC ATTITUDES, BELIEFS AND KNOWLEDGE ABOUT SMALLPOX

Hepatitis B and C Basics

Greater Glasgow and Clyde. Blood Borne Viruses: Some important basic facts

11/8/2016. The Challenge of HIV Treatment

Human immunodeficiency virus (HIV) is the virus that causes acquired immune. Drug Abuse and HIV. Research Report Series. Research Report Series

Population-specific Challenges Contributing to Disparities in Delivery of Care

What is Hepatitis? easy read A B C

YOU ARE NOT ALONE Health and Treatment for HIV Positive Young Men of Color

Are You Positive You re Negative?

Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers

Responsibilities in a sexual relationship - Contact tracing

Americans Current Views on Smoking 2013: An AARP Bulletin Survey

Fast-Track Your PrEP Knowledge. Jonathan Fritz PrEP Coordinator MDHHS Division of HIV and STD Programs

Office of Clinical Research. Information for Participants

Prescription for Progress Study conducted by the Siena College Research Institute April 10 - May 4, Stakeholders - MOE +/- 4.

www. russellresearch.com

STI and HIV Prevention and Care among Sex Workers

Public Perception of Clinical Research

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

What is HIV? H -uman. I -mmunodefiency. V -irus Type of germ Lives and reproduces in body cells

Important Safety Information for Adolescents Who Don t Have HIV

Version for the Silent Procedure 29 April Agenda item January Hepatitis

HIV/AIDS INDICATORS. AIDS Indicator Survey 8 Basic Documentation Introduction to the AIS

PHSKC HIV Testing Survey: Knowledge, Attitudes and Practices

One daily pill can help prevent HIV. TRUVADA for PrEP, together with safer sex practices, can mean better protection.

Patient-Centered Hepatitis C Virus (HCV) Care Via Telemedicine for Individuals on Opiate Agonist Treatment Marija Zeremski, PhD

NATIONAL SURVEY OF YOUNG ADULTS ON HIV/AIDS

I S H I V S O R T E D? S U R V E Y H I G H L I G H T S

What is injection drug use?

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

EVALUATION TOOLS...123

HIV WHAT WORKERS NEED TO KNOW

Module 7: Healthy Living

People who experience gender based violence are more at risk of HIV.

HIV and the Buckeye State

Cross-Border Cooperation in the Global Fight against Communicable Diseases

Minneapolis Department of Health and Family Support HIV Surveillance

Culminating Assessments. Option A Individual Essay. Option B Group Research Proposal Presentation

MODULE 3 FLORIDA DEPARTMENT OF HEALTH STUDY GUIDE HIV/AIDS: 101 WEMAKETHECHANGE.COM

Responding to HIV/AIDS in Illinois Remarks to the Adequate Health Care Task Force

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

As a result of this training, participants will be able to:

Government of Canada Federal AIDS Initiative Milestones

Study Plan: Screening

Understanding contraceptive choices among a cohort of HIV-positive women

Hepatitis C: Get the Facts. a workbook

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

High School Sexual Health Curriculum Overview

Learning about HIV. A Lesson Plan from Rights, Respect, Responsibility: A K-12 Curriculum

Informed Consent Flipchart. Version 1.0, 30 Jan 2018

KEY FINDINGS FROM THE 2005 MYRBS

Arizona State Office of Rural Health Webinar Series

HEPATITIS A & B VACCINATION

Clinical Trials Network

As a result of this training, participants will be able to:

Training of Peer Educator Ujenzi

TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers

Working Papers Project on the Public and Biological Security Harvard School of Public Health 17.

ELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD

National Viral Hepatitis Action Plan Priority Populations Approach

The role of UNODC in working law enforcement agencies to promote harm reduction. IHRC, Bangkok, 23 April 2009

PROTECT YOURSELF + PROTECT YOUR PARTNER. syphilis THE FACTS

Welcome to Your Reading Assignment

HIV in the UK: Changes and Challenges; Actions and Answers The People Living With HIV Stigma Survey UK 2015 Scotland STIGMA SURVEY UK 2015

HIV/ AIDS Agricultural Worker Factsheet

Ethical risks and remedies in social behavioral research involving genetic testing

Progress against the HIV Epidemic: is the end in sight?

Knowledge, Attitudes and Behavior Related to HIV/AIDS among Transport Sector Workers

Malaria prevention and control

Elton Naswood, Michelle Enfield & Mattee Jim

Human Journals Research Article July 2018 Vol.:10, Issue:1 All rights are reserved by Gogochashvili S.

Addressing STIs among MSM: A Clinical and Public Health Update

There are two supplemental tables presented here. The first, Table A.1, compares the items in the

HIV AND PEOPLE WHO INJECT DRUGS

Who this handbook is for?

CALM LEARNER OUTCOMES 1 :

MOTIVATION FOR CHANGE: OVERCOMING HELPLESSNESS

HEPATITIS C LESSONS PART 4

National Survey of Young Adults on HIV/AIDS

Nikhil Prachand, MPH Britt Skaathun

THE UNIVERSITY OF NAIROBI REPORT ON HIV/AIDS AND ADA SENSITIZATION ACTIVITY AMONG THE STAFF MEMBERS

What You Must Know about Hepatitis C. Facts, Symptoms, Treatment and Cures

Transcription:

Assessing and Enhancing HIV Vaccine Trial (HVT) Consent Preparedness Among Street Drug Users Celia B. Fisher, Ph.D. Marie Ward Doty University Chair Director, Center for Ethics Education Fisher@Fordham.edu HIV Prevention Research Ethics Institute Summer 2013

Fisher, C. B. (2010). Enhancing HIV trial consent preparedness among street drug users. Journal of Empirical Research on Human Research Ethics, 5, 65-80. PMID: 20569151. (NIDA 1R01DA015649-01A1).

Is it fair to study HIV vaccine in drug using impoverished populations in the US? Are we asking this population to carry an unjust burden of experimentation that we are not asking of better off populations that will benefit from the results of the study?

Injection drug use accounts for 1/3 HIV cases in US Increased risk from IDU, sex work, & unprotected sex Difficult to develop a universally effective vaccine without testing its efficacy in IDUs Course of infection through sexual transmission and injection Effect of street drugs on viral strains Differences in immunological barriers Drug-drug interactions Comorbidities

General Consent Vulnerabilities Health disparities Education Cognitive impairments Co-morbid mental health disorders Poverty Social Stigma Legal risk

HVT Consent Vulnerabilities Misconceptions HIV acquisition and transmission Purpose of vaccine (preventive v. curative) Nature of HVT (injection of virus; increased risks; AIDS safe) Mistrust Group stigma History of research abuses Health disparities

Goodness-of Fit Ethics Consent vulnerability = joint product of participant characteristics and the research context. Shared burden for consent vulnerability. Increase consent capacity by fitting research and consent context to participants strengths and vulnerabilities Fisher, 1997, 1999; Fisher 2002, Fisher & Goodman, 2009; Fisher & Ragsdale, 2006

Research Ethics Questions What experiences, knowledge and attitudes characterize HVT consent preparedness among marginalized persons who use street drugs? Can a brief lesson fitted to this population s needs correct misconceptions and increase HVT relevant knowledge? Can a brief lesson reduce research mistrust?

Procedure Street recruitment Informed consent Demographics Health care experience & attitudes Baseline measures N = 96 Lesson N = 30 Post-lesson measures N = 30 Compensation $25

96 HIV Negative Street F O R Drug D H A M U Users N I V E R S I T Y Center for Ethics Education, Director, Celia B. Fisher, Ph.D. Demographics 45% Male 21-57 years, M = 40 90% unemployed 48% homeless/shelter 66% high school degree 72% time in prison Ethnicity 33% Black non-hispanic 23% Hispanic (Puerto Rican) 43% non-hispanic White 1% other Commonly used drugs 97% IDU past year 72% cocaine 91% heroin 36% marijuana HIV attitudes & risk factors 45% shared needles 44% rarely use condoms 96% worried about HIV 16% men MSM 78% women WSM

Health Care Experience Healthcare 96% tested for HIV 99% received health care past 12 months 100% were vaccinated Reasons for Perceived Health Disparities (Blendon et al, 2007) 59% professionals lack training 40% inability to pay 41% racial/ethnic discrimination 42% not take my health insurance How much do you worry about HIV? 96% somewhat (Scale 0 3)

11 True False Questions Tapping HIV& Vaccine Knowledge HIV KNOWLEDGE 84 100% VACCINE KNOWLEDGE Vaccine is a treatment for people infected with a disease 47% MISTRUST HIV is a manmade virus created to get rid of certain groups 29% An effective HIV vaccine has been withheld from the public 58% The government is keeping a cure for AIDS from the public 50%

HVT Knowledge and Misconceptions KNOWLEDGE 80% - 90% Equipoise, placebo, blood tests MISCONCEPTIONS 40% 84% (5 items) Participants and doctors will know whether they are given vaccine or placebo Individuals with HIV can participate in an HVT An HIV vaccine will NOT produce false positive HIV tests The vaccine contains the HIV virus The vaccine increases acquisition and transmission of HIV

HVT Mistrust 53% - 83% of Respondents: Gov t does NOT test the safety of a vaccine before giving it to participants Scientists use addicts as guinea pigs for vaccine for better offs Scientist will NOT be honest about HVT risks Vaccine studies sponsored by the gov t or pharmaceutical companies will not report results honestly

HIV Vaccine Research Researchers are testing whether new medications can prevent HIV These research studies are called Experimental HIV Vaccine Studies or HIV Vaccine Clinical Trials For each study, researchers do not know if the vaccine works until the study is over

What is a Vaccine? A vaccine is a drug that prevents people from getting a disease, like hepatitis or polio. There is NO vaccine for HIV

Researchers test whether the new vaccine works by comparing its effects to a placebo Half the people who agree to participate receive the experimental vaccine Half receive a placebo (a sugar pill or an injection that does not contain any medicine)

Randomization Everyone who volunteers has an equal chance of being in the experimental vaccine or placebo group. This is called randomization and it is like a coin toss. Neither volunteers nor researchers can choose which group people will be in. Neither the volunteer or the researchers know who is getting the vaccine or placebo until the study is over.

Side Effects of the Vaccine Side effects from the experimental vaccine are usually short-term and mild such as arm soreness, fever, headache or tiredness. Fordham University Center for Ethics Education 19

Who Can Participate? Because the purpose of a experimental vaccine is to prevent people from getting HIV, Only people who are HIV negative can participate. Therefore, to qualify to be in the study everyone must take an HIV test. Fordham University Center for Ethics Education 20

What Can I Expect if I Participate? Experimental vaccine studies usually last for 1 or 2 years and requires about 6 20 visits. Most visits require participants to take a blood test and visits last anywhere from 30 minutes to 3 hours. Participants are paid between $50 - $150 or more a visit depending on how long the visit lasts. Fordham University Center for Ethics Education 21

How Will Researchers Know Whether the Vaccine Works? Blood tests will tell whether people getting the vaccine build up antibodies that can fight the HIV virus At the end of the study researchers will see whether people who received the vaccine were less likely to get HIV than those who received the placebo. Fordham University Center for Ethics Education 22

The Vaccine DOES NOT Contain the HIV Virus The vaccine is made from artificial material and does not contain the HIV virus. The vaccine is designed to make the body build up its own defenses against the HIV virus. Fordham University Center for Ethics Education 23

YOU CANNOT GET HIV FROM THE VACCINE YOU CANNOT TRANSMIT HIV TO OTHERS IF YOU TAKE THE VACCINE Fordham University Center for Ethics Education 24

False Positive HIV Tests Since one way doctors usually diagnosis HIV is to test the body defenses to the virus, people who participate in an HIV vaccine study may test positive for HIV even though they do not have HIV Researchers will use special tests during the study that will provide correct test results. Fordham University Center for Ethics Education 25

Participation is Voluntary & Confidential Participation in these studies is always voluntary and all the facts about the study are explained to each person before they are asked if they want to participate. All information is given the same confidentiality protection as other medical records Fordham University Center for Ethics Education 26

Did Lesson Reduce Misconceptions? Item Pre Post Participant blind 63% 13% Investigator blind 93% 27% HIV+ can participate in HVT 60% 13% HVT produces false-positive HIV test 37% 90% Vaccine contains HIV 33% 10% Can get HIV from HVT 33% 13% HVT increases chance of transmission 43% 3%

Did HVT Lesson Reduce Mistrust? Item Pre Post Gov t does not test safety before giving vaccine 70% 57% Scientist will NOT be honest about HVT risks 73% 53% Vaccine studies sponsored by the gov t will not report results honestly Scientists use addicts as guinea pigs for vaccine for better offs 81% 60% 73% 73%

Post-Lesson Questions Ethics Relevant Questions % AIDS-safe increase in risk behaviors (participant) 0 7% AIDS-safe increase in risk behaviors (Other drug users) 27% Participation benefits: HIV Protection, counseling, benefit others 83-90% Participant risks: Placebo & weekly blood tests 27-10% Participant risks: Not take vaccine unless FDA approved 63% Consent: Most will understand consent But long term addicts may not understand placebo 87% 40%

Voluntariness Drug addicts should worry that if the say no to participate in the vaccine trial, other doctors at the clinic will not treat them 13% No matter how much money is offered, if people with drug addictions thought the experimental vaccine study was dangerous they would refuse to be in it 55% If there is money being offered drug addicts won t care about the risks of being in the study 77%

Implications for Goodness of Fit Practices A brief intervention significantly increases street drug users understanding of consent information Under GFE investigators have a responsibility to include educational procedures in consent practices Understanding consent information is not the same as believing in the honesty of the information provided Such procedures may be necessary, but not sufficient in the context of health disparities and systemic discrimination